title: [The influence of anticancer agents at various stages to induce LAK cell on its cytotoxicity and cell yield. Examination in vitro].
abstract: To establish the combination of chemotherapy with adoptive immunotherapy (AIT), using lymphokine activated killer cells (LAK) and/or interleukin-2 (IL-2), author examined the following: 1) Pretreatment with anticancer agents for peripheral blood mononuclear cells (PBMC) and its effect on LAK cell cytotoxicity and cell yield. 2) The addition of anticancer agents in the induction phase to LAK cell and its effect on LAK cell cytotoxicity and cell yield. 3) Pretreatment with anticancer agents to induced LAK cell and its effect on LAK cell cytotoxicity and cell yield. 4) The cytotoxicity of LAK cell against tumor cells treated with anticancer agents. Our experiment has shown that when we take peripheral blood mononuclear cells (PBMC) to induce LAK cells, there is no influence on its LAK cell yield or its cytotoxicity after being harvested as LAK cells, even if there is a maximum concentration of anticancer agents, but in the case of the LAK cell induction phase VDS, CDDP, ADM and MMC have a significant effect on LAK cell yield and on cytotoxicity of LAK cell after being harvested as LAK cells. And it has also been shown that, if there is a maximum concentration of anticancer agents, it has an effect on the induced LAK cell cytotoxicity and on the LAK cell yield after being recultured with IL-2. On the other hand, LAK cell cytotoxicity makes no difference to tumor cells whether they are treated or not with anticancer agents. These results suggest that we can take peripheral blood mononuclear cells to induce LAK cells unrelated to the administration of anticancer agents, and that if we use a combination of chemotherapy with adoptive immunotherapy (IL-2 administration and/or LAK cell adaptation), we should start with the administration of anticancer agents and then administer IL-2 and/or transfer LAK cells after the concentration of anticancer agents decreased under 1/10 of maximum concentration in the blood level of our conventionally clinical use.
authors.affiliation: Department of Clinical Pathology, Nippon Medical School, Tokyo, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Baba
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D003131:Combined Modality Therapy; D003602:Cytotoxicity, Immunologic / Q000187:drug effects*; D006801:Humans; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000494:pharmacology*; D015979:Killer Cells, Lymphokine-Activated / Q000276:immunology* / Q000637:transplantation; D008213:Lymphocyte Activation / Q000187:drug effects*; D009369:Neoplasms / Q000473:pathology*; D011994:Recombinant Proteins; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents; D007376:Interleukin-2; D011994:Recombinant Proteins